Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-17 22:30 |
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
|
English | 161.7 KB | ||
| 2023-11-15 08:30 |
Cellectis Announces the execution of the Subsequent Investment Agreement with A…
|
English | 201.3 KB | ||
| 2023-11-15 08:30 |
Cellectis Annonce la signature de l’Accord d’Investissement Définitif avec Astr…
|
French | 226.4 KB | ||
| 2023-11-06 22:30 |
Cellectis publie ses résultats financiers du troisième trimestre 2023
|
French | 511.9 KB | ||
| 2023-11-06 22:30 |
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
|
English | 381.2 KB | ||
| 2023-11-03 21:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 119.8 KB | ||
| 2023-11-03 21:30 |
Monthly information on share capital and company voting rights
|
English | 90.8 KB | ||
| 2023-11-02 21:30 |
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of t…
|
English | 140.2 KB | ||
| 2023-11-02 21:30 |
Cellectis présentera des données préliminaires de l’essai NATHALI_01 et des rés…
|
French | 169.1 KB | ||
| 2023-11-01 21:30 |
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
|
English | 138.3 KB | ||
| 2023-11-01 21:30 |
Cellectis présentera ses résultats financiers du troisième trimestre 2023 le 6 …
|
French | 152.7 KB | ||
| 2023-11-01 08:00 |
Cellectis Announces Strategic Collaboration and Investment Agreements with Astr…
|
English | 76.8 KB | ||
| 2023-11-01 08:00 |
Cellectis Annonce une Collaboration Stratégique et un Accord d'Investissement A…
|
French | 74.2 KB | ||
| 2023-10-31 21:30 |
Cellectis présente des données précliniques sur des cellules « smart » MUC1- CA…
|
French | 165.5 KB | ||
| 2023-10-31 21:30 |
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cel…
|
English | 155.7 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
